A Phase I/IIA, Multicentre, Two Parts, Open-Label Study Designed to Evaluate the Safety and Tolerability of Escalating Doses of AGI-134 in Unresectable/Metastatic Solid Tumours
Latest Information Update: 07 Feb 2024
At a glance
- Drugs AGI 134 (Primary)
- Indications Breast cancer; Cervical cancer; Colon cancer; Endometrial cancer; Malignant melanoma; Sarcoma; Solid tumours; Squamous cell cancer; Synovial sarcoma
- Focus Adverse reactions; First in man
- Sponsors Agalimmune
- 31 Jan 2024 Status changed from active, no longer recruiting to completed.
- 20 Dec 2022 According to a BioLineRx media release, complete data will be published at a medical congress in 2023.
- 20 Dec 2022 Results published in the BioLineRx media release.